GRFS

Grifols, S.A.

Price Chart

Latest Quote

$7.18

-0.10 (-1.37%)

Current Price

Previous Close	$7.28
Open	$7.38
Day High	$7.40
Day Low	$7.16
Volume	646,653

Fetched: 2026-06-24T10:27:54

Stock Information

Note: Financial values converted from EUR to USD

Quarterly Dividend / Yield	$0.27 / 3.76%
Shares Outstanding	258.22M
Quarterly Dividend Yield	3.76%
Quarterly Dividend	$0.27
Total Debt	$10.97B
Cash Equivalents	$796.28M
Revenue	$8.44B
Net Income	$470.73M
Sector	Healthcare
Industry	Drug Manufacturers - General
Market Cap	$4.89B
P/E Ratio	10.26
EPS (TTM)	$0.70
Exchange	NMS

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$21.13B
Sales	$8.44B
Income	$470.73M
Book/sh	$4.67
Cash/sh	$2.72
Employees	25K

Financial Ratios

Quick Ratio	0.78
Current Ratio	2.47
Debt/Eq	123.22
EPS Growth TTM	22.20%

Returns & Margins

ROA	4.21%
ROE	6.13%
Gross Margin	38.36%
Operating Margin	16.47%
Profit Margin	5.58%

Ownership

Institutional Ownership	58.21%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	4.97
PEG	0.19
P/S	0.66
P/B	1.54

Analyst Data

Recommendation	none
Target Price	$10.87

Technical Indicators

SMA20	$7.58
SMA50	$7.92
SMA200	$8.75
RSI	34.48
ATR	0.1857

Shares Float	834.63M
Short Ratio	10.39
Volatility	1.17
Rel Volume	1.05

Performance History

Week	-5.77%
Month	-11.47%
Quarter	-6.63%
6 Months	-19.51%
YTD	-22.29%
Year	-16.77%
3 Years	-18.63%
5 Years	-60.03%
10 Years	-47.45%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-23	$7.18	656,300
2026-06-22	$7.28	691,100
2026-06-18	$7.40	1,025,900
2026-06-17	$7.46	625,600
2026-06-16	$7.59	269,100
2026-06-15	$7.62	394,500
2026-06-12	$7.64	480,300
2026-06-11	$7.49	702,500
2026-06-10	$7.32	830,100
2026-06-09	$7.34	1,026,400
2026-06-08	$7.33	569,400
2026-06-05	$7.64	338,400
2026-06-04	$7.58	390,500
2026-06-03	$7.47	474,500
2026-06-02	$7.63	583,200
2026-06-01	$7.74	1,010,700
2026-05-29	$7.85	626,400
2026-05-28	$7.98	523,300
2026-05-27	$8.05	757,500
2026-05-26	$8.01	487,600

About Grifols, S.A.

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as well as provides transfusion medicine, clinical diagnostics, and testing services. It also offers biological products, including albumin, albumin-derived products, immunoglobulins, thrombin, other proteins, and intermediate plasma products to pharma and biotech companies for biopharma use; and whole blood, blood components, processed plasma, and clinical samples to life-science research and in-vitro diagnostic companies for diagnostic use. In addition, the company provides healthcare solutions for hospitals, such as intravenous solutions to maintain or restore fluids and electrolyte balance in patients; high-tech solutions to automate hospital processes; clinical nutrition to deliver nutrition and medication; and medical devices comprising instrumentation and disposable materials for various hospital services, which include interventional neuroradiology, hemodynamics, urology, anesthesiology and cardiovascular surgery, as well as manufacturing services to third parties and research activities. Further, it is involved in engineering services; packaging, labelling, storage, distribution, manufacturing, and development of pharmaceutical products; import, export, and commercialization activities; travel agency services; reinsurance of insurance policies; support services; law business; and consultation, administration, and financing services. The company was founded in 1909 and is headquartered in Barcelona, Spain.

📰 Latest News

Grifols (GRFS) Launches FESILTY in the U.S. for Congenital Fibrinogen Deficiency Treatment

Insider Monkey • 2026-06-19T16:52:31Z

European Equities Traded in the US as American Depositary Receipts Track Higher in Tuesday Trading

MT Newswires • 2026-06-09T15:11:39Z

European Equities Traded in the US as American Depositary Receipts Start Week Higher in Monday Trading

MT Newswires • 2026-06-08T15:10:25Z

Grifols, S.A. (GRFS) Sees Strong Biopharma Growth Led by Gamunex and Yimmugo

Insider Monkey • 2026-06-02T14:10:35Z

European Equities Traded in the US as American Depositary Receipts Edge Lower Thursday

MT Newswires • 2026-05-28T15:14:11Z

How The Grifols (BME:GRF) Investment Story Is Shifting With New Analyst Caution

Simply Wall St. • 2026-05-23T19:08:59Z

European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading

MT Newswires • 2026-05-22T15:06:28Z

European Equities Traded in US as ADRs Rise in Wednesday Trading

MT Newswires • 2026-05-20T15:03:01Z

European Equities Traded in the US as American Depositary Receipts Open Week Tracking Higher in Monday Trading

MT Newswires • 2026-05-18T15:11:28Z

European Equities Traded in the US as American Depositary Receipts Start Week on Flat Note in Monday Trading

MT Newswires • 2026-05-11T15:05:40Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Reconciled Cost Of Revenue	$4,966,773,796	$4,688,359,487	$4,319,431,883	$4,041,400,250
Cost Of Revenue	$5,344,867,304	$5,061,870,042	$4,707,837,031	$4,411,385,370
Total Revenue	$8,620,531,960	$8,263,061,735	$7,552,704,237	$6,947,716,816
Operating Revenue	$8,342,117,650	$8,024,748,252	$7,318,973,705	$6,661,093,294
Expenses
Interest Expense	$659,945,030	$689,734,216	$591,200,756	$509,329,763
Total Expenses	$7,187,213,847	$6,939,734,460	$6,730,064,425	$6,169,808,903
Other Income Expense	$-35,517,875	$-11,457,379	$54,995,419	$139,459,217
Net Non Operating Interest Income Expense	$-693,171,430	$-803,162,268	$-641,613,224	$-530,092,826
Total Other Finance Cost	$72,181,488	$163,840,520	$121,448,217	$59,556,602
Interest Expense Non Operating	$659,945,030	$689,734,216	$591,200,756	$509,329,763
Operating Expense	$1,842,346,543	$1,877,864,418	$2,022,227,394	$1,758,423,534
Other Operating Expenses	$-1,145,738	-	$-3,437,214	$-25,475,482
General And Administrative Expense	$1,217,919,388	$1,309,578,420	$1,450,504,181	$1,269,236,988
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$460,586,636	$179,880,850	$48,120,992	$212,001,612
Net Interest Income	$-693,171,430	$-803,162,268	$-641,613,224	$-530,092,826
Interest Income	$38,955,089	$50,412,468	$71,035,750	$38,793,540
Normalized Income	$482,010,789	$220,268,111	$61,719,677	$195,427,629
Net Income From Continuing And Discontinued Operation	$460,586,636	$179,880,850	$48,120,992	$212,001,612
Total Operating Income As Reported	$1,424,152,210	$1,365,719,577	$895,967,038	$896,466,580
Net Income Common Stockholders	$460,586,636	$179,880,850	$48,120,992	$212,001,612
Net Income	$460,586,636	$179,880,850	$48,120,992	$212,001,612
Net Income Including Noncontrolling Interests	$572,868,950	$244,042,173	$186,755,278	$284,030,717
Net Income Continuous Operations	$572,868,950	$244,042,173	$186,755,278	$284,030,717
Pretax Income	$704,628,808	$508,707,628	$236,022,007	$387,274,305
Special Income Charges	$-3,437,214	$-10,311,641	$0	$0
Earnings From Equity Interest	$-9,165,903	$42,392,302	$72,181,488	$116,860,683
Interest Income Non Operating	$38,955,089	$50,412,468	$71,035,750	$38,793,540
Operating Income	$1,433,318,113	$1,323,327,274	$822,639,812	$777,907,913
Depreciation Amortization Depletion Income Statement	$137,488,548	$128,322,645	$122,593,955	$100,890,242
Depreciation And Amortization In Income Statement	$137,488,548	$128,322,645	$122,593,955	$100,890,242
Gross Profit	$3,275,664,656	$3,201,191,693	$2,844,867,206	$2,536,331,447
Per Share
Diluted EPS	$0.68	$0.26	$0.10	$0.36
Basic EPS	$0.68	$0.26	$0.10	$0.36
Other
Tax Effect Of Unusual Items	$-4,927,819	$-13,462,420	$-3,587,383	$6,024,551
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$1,906,507,866	$1,754,124,725	$1,355,407,936	$1,344,880,896
Total Unusual Items	$-26,351,972	$-53,849,681	$-17,186,068	$22,598,534
Total Unusual Items Excluding Goodwill	$-26,351,972	$-53,849,681	$-17,186,068	$22,598,534
Reconciled Depreciation	$515,582,055	$501,833,200	$510,999,103	$470,875,362
EBITDA (Bullshit earnings)	$1,880,155,894	$1,700,275,044	$1,338,221,867	$1,367,479,430
EBIT	$1,364,573,839	$1,198,441,843	$827,222,764	$896,604,068
Diluted Average Shares	$780,904,184	$779,006,349	$778,822,549	$778,878,516
Basic Average Shares	$779,689,038	$778,722,018	$778,822,549	$778,878,516
Diluted NI Availto Com Stockholders	$460,586,636	$179,880,850	$48,120,992	$212,001,612
Minority Interests	$-112,282,314	$-64,161,322	$-138,634,286	$-72,029,105
Tax Provision	$131,759,859	$264,665,455	$49,266,730	$103,243,588
Write Off	$3,437,214	$10,311,641	$0	$0
Gain On Sale Of Security	$-22,914,758	$-43,538,040	$-17,186,068	$22,598,534
Research And Development	$488,084,345	$439,963,354	$452,566,471	$413,771,785
Selling General And Administration	$1,217,919,388	$1,309,578,420	$1,450,504,181	$1,269,236,988
Other Gand A	$1,217,919,388	$1,309,578,420	$1,450,504,181	$1,269,236,988
Gain On Sale Of Ppe	-	-	$-28,635,427	$-20,853,576
Salaries And Wages	-	-	$605,847,870	$541,261,479

Fetched: 2026-06-22

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$-4,915,215,591	$-5,093,950,703	$-4,887,657,157	$-4,941,032,503
Total Assets	$22,584,785,485	$24,524,519,750	$24,051,448,008	$24,323,538,990
Total Non Current Assets	$16,771,311,380	$17,961,733,058	$17,026,910,611	$18,949,198,725
Non Current Prepaid Assets	$18,331,806	$10,311,641	$10,164,987	$10,629,010
Non Current Deferred Assets	$476,626,966	$391,842,362	$344,098,318	$200,415,911
Non Current Deferred Taxes Assets	$476,626,966	$391,842,362	$344,098,318	$200,415,911
Non Current Note Receivables	$152,383,141	$22,914,758	$156,537,586	$125,684,010
Financial Assets	$0	$1,145,738	$1,195,005	$30,969,295
Investmentin Financial Assets	$415,902,858	$527,039,434	$34,525,666	$568,988,336
Financial Assets Designatedas Fair Value Through Profitor Loss Total	$2,291,476	$5,728,690	$8,020	-
Goodwill And Other Intangible Assets	$10,954,400,062	$11,834,326,769	$11,038,409,002	$11,412,759,383
Other Intangible Assets	$3,125,572,991	$3,352,429,095	$3,244,954,297	$3,378,949,491
Current Assets	$5,813,474,105	$6,562,786,691	$7,024,537,397	$5,374,340,265
Other Current Assets	$74,472,964	$82,493,129	$84,718,152	$94,726,172
Hedging Assets Current	$0	$6,874,427	$27,089,827	$14,469,524
Restricted Cash	$27,497,710	$0	-	-
Prepaid Assets	$10,311,641	$11,457,379	$5,127,177	$22,218,149
Inventory	$3,776,352,118	$4,078,826,924	$3,989,916,517	$3,707,619,302
Receivables	$980,751,642	$1,236,251,194	$1,045,138,675	$887,027,991
Other Receivables	$138,634,286	$60,724,109	$98,472,735	$124,123,515
Taxes Receivable	$82,493,129	$122,593,955	$91,429,884	$65,057,289
Loans Receivable	$13,748,855	$245,187,911	$116,105,642	$54,995
Accounts Receivable	$745,875,373	$807,745,220	$739,130,414	$697,847,186
Allowance For Doubtful Accounts Receivable	$-26,351,972	$-24,060,496	$-36,177,820	$-36,997,023
Gross Accounts Receivable	$772,227,345	$831,805,715	$775,308,234	$734,393,933
Cash Cash Equivalents And Short Term Investments	$944,088,030	$1,146,883,638	$623,857,724	$664,804,105
Cash And Cash Equivalents	$917,736,058	$1,122,823,142	$606,756,440	$629,247,275
Cash Equivalents	$9,165,903	$5,728,690	$7,454,171	$5,729
Cash Financial	$908,570,155	$1,117,094,452	$599,302,269	$627,840,309
Other Non Current Assets	-	$156,966,092	$155,401,014	$142,290,336
Non Current Accounts Receivable	-	$67,599	-	-
Assets Held For Sale Current	-	$0	$1,248,689,325	$5,693,172
Debt
Net Debt	$8,802,704,286	$9,155,591,559	$10,692,081,078	$9,378,096,151
Total Debt	$10,960,128,751	$11,586,847,383	$12,572,128,127	$11,171,087,742
Long Term Debt And Capital Lease Obligation	$10,360,907,830	$10,821,494,466	$11,440,243,344	$10,390,527,446
Long Term Debt	$9,250,687,805	$9,647,113,118	$10,289,662,410	$9,342,649,311
Current Debt And Capital Lease Obligation	$599,220,922	$765,352,917	$1,131,884,783	$780,560,296
Current Debt	$469,752,539	$631,301,583	$1,009,175,108	$663,287,148
Other Current Borrowings	$469,752,539	$631,301,583	$1,009,175,108	$663,287,148
Liabilities
Total Liabilities Net Minority Interest	$13,873,740,231	$14,664,299,382	$15,442,722,877	$15,184,985,699
Total Non Current Liabilities Net Minority Interest	$11,560,495,411	$12,194,088,470	$12,778,374,698	$12,871,424,656
Other Non Current Liabilities	$57,286,895	$53,849,681	$55,624,429	$11,542,358,380
Derivative Product Liabilities	$1,145,738	$0	$12,603	$4,586,389
Non Current Deferred Liabilities	$1,004,812,138	$1,175,527,085	$1,148,528,918	$1,202,962,925
Non Current Deferred Taxes Liabilities	$986,480,332	$1,159,486,755	$1,132,709,714	$1,185,635,931
Current Liabilities	$2,313,244,820	$2,470,210,912	$2,664,348,179	$2,313,561,044
Other Current Liabilities	$91,659,032	$48,120,992	$49,013,522	$1,196,561,688
Current Deferred Liabilities	$38,955,089	$49,266,730	$44,904,906	$43,347,848
Payables And Accrued Expenses	$1,543,308,951	$1,562,786,496	$1,383,771,823	$1,052,449,629
Payables	$1,543,308,951	$1,562,786,496	$1,383,771,823	$1,052,449,629
Other Payable	$522,456,482	$488,084,345	$398,752,307	$131,676,220
Total Tax Payable	$57,286,895	$98,533,459	$42,131,074	$17,973,190
Income Tax Payable	$28,643,448	$69,890,012	$16,639,552	$17,973,190
Accounts Payable	$963,565,574	$976,168,691	$942,888,442	$902,800,219
Equity
Common Stock Equity	$6,039,184,471	$6,740,376,066	$6,150,751,845	$6,471,726,880
Total Equity Gross Minority Interest	$8,711,045,254	$9,860,220,367	$8,608,725,131	$9,138,553,291
Stockholders Equity	$6,039,184,471	$6,740,376,066	$6,150,751,845	$6,471,726,880
Gains Losses Not Affecting Retained Earnings	$4,664,298,991	$5,533,914,057	$5,096,785,259	$5,477,098,060
Other Equity Adjustments	$4,788,038,684	$4,634,509,806	$4,622,321,446	$4,634,090,465
Retained Earnings	$343,721,370	$179,880,850	$48,485,336	$0
Long Term Equity Investment	$111,136,576	$79,055,915	$483,229,854	$1,716,268,399
Other
Treasury Shares Number	$7,996,788	$8,187,218	$9,695,955	$10,476,873
Ordinary Shares Number	$779,760,929	$779,570,498	$778,061,762	$777,280,844
Share Issued	$787,757,716	$787,757,716	$787,757,716	$787,757,716
Tangible Book Value	$-4,915,215,591	$-5,093,950,703	$-4,887,657,157	$-4,941,032,503
Invested Capital	$15,759,624,815	$17,018,790,767	$17,449,589,363	$6,471,726,880
Working Capital	$3,500,229,285	$4,092,575,779	$4,360,189,217	$3,060,779,221
Capital Lease Obligations	$1,239,688,408	$1,308,432,682	$1,273,290,609	$1,165,151,283
Total Capitalization	$15,289,872,276	$16,387,489,184	$16,440,414,255	$6,471,726,880
Minority Interest	$2,671,860,783	$3,119,844,302	$2,457,973,286	$2,666,826,410
Foreign Currency Translation Adjustments	$-11,457,379	$920,027,534	$474,463,813	$843,007,595
Unrealized Gain Loss	$-112,282,314	$-20,623,282	$0	$0
Treasury Stock	$150,091,665	$154,674,616	$175,009,173	$185,861,602
Additional Paid In Capital	$1,043,767,227	$1,043,767,227	$1,043,455,586	$1,043,455,586
Capital Stock	$137,488,548	$137,488,548	$137,034,836	$137,034,836
Common Stock	$137,488,548	$137,488,548	$137,034,836	$137,034,836
Non Current Deferred Revenue	$18,331,806	$16,040,331	$15,819,203	$17,326,994
Long Term Capital Lease Obligation	$1,110,220,025	$1,174,381,348	$1,150,580,934	$1,047,878,134
Long Term Provisions	$136,342,810	$143,217,238	$133,965,404	$126,103,350
Current Deferred Revenue	$38,955,089	$49,266,730	$44,904,906	$43,347,848
Current Capital Lease Obligation	$129,468,383	$134,051,334	$122,709,675	$117,273,148
Current Provisions	$40,100,826	$44,683,778	$54,773,146	$64,549,728
Investments And Advances	$527,039,434	$606,095,349	$517,755,520	$2,285,256,735
Available For Sale Securities	$413,611,382	$521,310,745	$34,517,646	$568,988,336
Goodwill	$7,828,827,071	$8,481,897,674	$7,793,454,705	$8,033,809,893
Net PPE	$4,642,529,971	$4,938,130,349	$4,803,349,180	$4,908,476,361
Accumulated Depreciation	$-3,051,100,028	$-3,024,748,056	$-2,607,547,077	$-2,387,087,628
Gross PPE	$7,693,629,999	$7,962,878,405	$7,410,896,257	$4,908,476,361
Leases	$1,491,750,746	$1,518,102,718	$1,393,284,885	$1,277,101,333
Construction In Progress	$831,805,715	$918,881,796	$1,043,389,133	$1,006,433,357
Machinery Furniture Equipment	$3,984,876,416	$4,115,490,537	$3,677,347,761	$3,555,756,326
Land And Improvements	$1,385,197,121	$1,410,403,355	$1,296,874,478	$1,323,792,444
Properties	$0	$0	$0	$0
Inventories Adjustments Allowances	$-113,428,052	$-171,860,685	-	-
Finished Goods	$1,205,316,271	$1,435,609,589	$1,351,985,617	$922,246,828
Work In Process	$1,612,053,225	$1,693,400,616	$1,386,440,247	$1,525,715,000
Raw Materials	$1,072,410,674	$1,121,677,404	$1,251,490,654	$1,219,954,218
Other Short Term Investments	$26,351,972	$24,060,496	$17,101,284	$35,556,830
Employee Benefits	-	-	$114,755,962	$107,780,710
Non Current Pension And Other Postretirement Benefit Plans	-	-	$114,755,962	$107,780,710
Other Properties	-	-	-	$4,908,476,361

Fetched: 2026-06-22

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$714,940,450	$607,241,087	$-106,553,625	$-451,763,308
Operating Activities
Operating Cash Flow	$1,199,587,581	$1,033,455,586	$248,625,124	$-1,634,968
Cash Flow From Continuing Operating Activities	$1,199,587,581	$1,033,455,586	$248,625,124	$-1,634,968
Operating Gains Losses	$11,457,379	$-41,246,564	$-64,161,322	$-118,843,955
Investing Activities
Capital Expenditure	$-484,647,132	$-426,214,499	$-355,178,749	$-450,128,340
Investing Cash Flow	$-663,382,244	$1,015,123,779	$-451,420,733	$-2,287,033,774
Cash Flow From Continuing Investing Activities	$-663,382,244	$1,015,123,779	$-451,420,733	$-2,287,033,774
Net Other Investing Changes	-	$1,791,934,076	-	$104,689,509
Financing Activities
Financing Cash Flow	$-606,095,349	$-1,557,057,806	$197,066,919	$-188,933,325
Cash Flow From Continuing Financing Activities	$-606,095,349	$-1,557,057,806	$197,066,919	$-188,933,325
Net Other Financing Charges	$-323,098,088	$-1,428,735,161	$329,972,515	$-64,806,373
Cash Dividends Paid	$-146,654,451	$-1,145,738	$0	$-678,277
Common Stock Dividend Paid	$-146,654,451	$-1,145,738	$0	-
Repurchase Of Capital Stock	-	$0	$0	$-3,963,107
Net Common Stock Issuance	-	$0	$0	$-3,963,107
Other
Repayment Of Debt	$-136,342,810	$-127,176,907	$-132,905,596	$-119,485,568
End Cash Position	$945,233,768	$1,122,823,142	$606,095,349	$629,247,275
Beginning Cash Position	$1,122,823,142	$606,095,349	$629,010,107	$3,066,117,214
Effect Of Exchange Rate Changes	$-107,699,363	$25,206,234	$-17,186,068	$40,732,128
Changes In Cash	$-69,890,012	$491,521,559	$-5,728,690	$-2,477,602,068
Net Issuance Payments Of Debt	$-136,342,810	$-127,176,907	$-132,905,596	$-119,485,568
Net Long Term Debt Issuance	$-136,342,810	$-127,176,907	$-132,905,596	$-119,485,568
Long Term Debt Payments	$-136,342,810	$-127,176,907	$-132,905,596	$-119,485,568
Net Investment Purchase And Sale	$-59,578,371	$-50,412,468	$-89,367,556	$-188,652,620
Sale Of Investment	$5,728,690	$0	$17,186,068	$0
Purchase Of Investment	$-65,307,060	$-50,412,468	$-106,553,625	$-188,652,620
Net Business Purchase And Sale	$-123,739,693	$-327,681,039	$-33,226,399	$-1,756,718,676
Purchase Of Business	$-123,739,693	$-327,681,039	$-33,226,399	$-1,756,718,676
Net Intangibles Purchase And Sale	$-181,026,588	$-159,257,568	$-98,533,459	$-124,964,487
Purchase Of Intangibles	$-181,026,588	$-159,257,568	$-98,533,459	$-124,964,487
Net PPE Purchase And Sale	$-299,037,592	$-239,459,221	$-230,293,318	$-321,387,501
Sale Of PPE	$4,582,952	$27,497,710	$26,351,972	$3,776,352
Purchase Of PPE	$-303,620,544	$-266,956,931	$-256,645,290	$-325,163,853
Taxes Refund Paid	$-193,629,705	$-201,649,870	$-182,172,326	$-225,064,170
Interest Received Cfo	$11,457,379	$12,603,117	$16,040,331	$4,644,821
Interest Paid Cfo	$-609,532,563	$-654,216,341	$-606,095,349	$-401,451,666
Change In Working Capital	$-35,517,875	$26,351,972	$-415,902,858	$-669,513,088
Change In Other Current Assets	$4,582,952	$11,457,379	$14,894,593	$-2,580,202
Change In Payables And Accrued Expense	$107,699,363	$33,226,399	$119,156,742	$144,955,322
Change In Payable	$107,699,363	$33,226,399	$119,156,742	$144,955,322
Change In Inventory	$-111,136,576	$29,789,185	$-470,898,277	$-723,100,395
Change In Receivables	$-36,663,613	$-48,120,992	$-79,055,915	$-88,787,813
Other Non Cash Items	$739,000,946	$797,433,578	$638,176,010	$470,262,392
Asset Impairment Charge	$56,141,157	$83,638,867	$115,719,528	$80,181,030
Depreciation Amortization Depletion	$515,582,055	$501,833,200	$510,999,103	$470,875,362
Depreciation And Amortization	$515,582,055	$501,833,200	$510,999,103	$470,875,362
Earnings Losses From Equity Investments	$9,165,903	$-42,392,302	$-72,181,488	$-116,860,683
Gain Loss On Sale Of PPE	$2,291,476	$1,145,738	$8,020,165	$-1,983,272
Net Income From Continuing Operations	$704,628,808	$508,707,628	$236,022,007	$387,274,305
Common Stock Payments	-	$0	$0	$-3,963,107
Sale Of Business	-	-	$0	$104,689,509

Fetched: 2026-06-22